BioCode for Better Health

 

Our Team

Advisors

Stephen Sun Chiao, Ph.D.

Sycamore Ventures, Managing Partner
Dr. Chiao is a Managing Partner of Sycamore Ventures in charge of technology investment. Since 2002, he has served on the investment committee for both SVC and AsiaStar investment funds. Over the last 15 years, he has served on the Board of Directors for many companies. Prior to joining Sycamore, Dr. Chiao held various senior management & technical positions at Gould/AMI, Hewlett-Packard and Varian Associates. He also advised several high-tech startups and investments in Silicon Valley. Dr. Chiao serves on the boards of ACM, Corrigo and TeleNav. He also serves as a senior advisor to AOI, Aplus Flash, illuminate, and Solargiga Energy.


Romney M. Humphries, Ph.D.

UCLA, Clinical Microbiology
Romney M Humphries, Ph.D., D(ABMM), M (ASCP)CM, is the Section Chief of Clinical Microbiology at the UCLA Health System and an Assistant Professor, in the Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA. She completed her Doctor of Philosophy degree in Bacterial Pathogenesis studying the bacterial pathogenesis at the University of Calgary, Canada. She completed a clinical postdoctoral fellowship in Medical and Public Health Laboratory Microbiology at UCLA. She is a Diplomate of the American Board of Medical Microbiology and a licensed Clinical Microbiologist. Her research interests are in antimicrobial susceptibility testing and resistance mechanisms, Clostridium difficile infection, diagnostics and pathogenesis, and in the development of rapid molecular tests for the detection, quantification, and characterization of microorganisms in clinical specimens for the diagnosis of infectious diseases.


Professor Nouri Neamati, Ph.D.

USC, School of Pharmacology Pharmacy
Neamati's work primarily focuses on cancer and HIV. He currently has compounds at various stages of development - from theoretical to in vitro to in vivo. Some of these compounds have been shown to work in experimental mouse disease models while exhibiting no toxicity. Collaborating with colleagues at the Norris Cancer Center, Neamati aims to take these promising therapeutics into clinical trials. His research has also developed compounds for diabetes, and through collaboration, has discovered a drug for muscular dystrophy that is currently in the early stages of development. Dr. Neamati obtained a Ph.D. in biomedical sciences from the University of Texas Graduate School of Biomedical Sciences and M.D. Anderson Cancer Center, Houston, Texas. From 1995-2000, he was a postdoctoral fellow and a research fellow at the National Institutes of Health. In September 2000, he joined the University of Southern California School of Pharmacy with a joint appointment at the Norris Comprehensive Cancer Center.


Professor William J. Rutter, Ph.D.

UCSF, Chiron Founder
In 1981 Dr. Rutter and two colleagues founded Chiron in an effort to explore the business applications and potential solutions to problems of human disease. He conducted Hepatitis B research, which resulted in development with Chiron and Merck of the vaccine for Hepatitis B, the first recombinant vaccine. Also at Chiron, he worked on the first sequencing of the HIV genome, and discovered, sequenced, and cloned the Hepatitis C virus. This opened the way for the development of diagnostic tests, therapeutic drugs, and vaccines against these viruses, and pioneered other projects aimed at therapy of cancer and metabolic disease. He founded Synergenics, L.L.C., a consortium of commonly owned but independent biotech companies organized to offer a cost-effective approach to startups in the life sciences industry. In late 2007, UCSF announced that Mission Bay's newest building, designed to facilitate communications between industry and the campus, would be named the "William Rutter Center". Dr. William J. Rutter earned a B.S. in biochemistry from Harvard University, a M.S. from the University of Utah and his Ph.D. in biochemistry at the University of Illinois.


Cheri Walker, Ph.D.

SFW Capital Partners, Operating Executive
Dr. Walker is the Chief Commercial Officer at SeraCare Life Sciences. Previously Dr. Walker was Senior Vice President of Corporate Development at Charles River Labs (NYSE: CRL) a leading contract research organization. Prior to Charles River, Dr. Walker was Vice President, Mergers and Acquisitions for Qiagen N.V (NASDAQ: QGEN), a leader in life science tools and molecular diagnostics. She was also previously a Vice President of the Proteomics Business Segment and Vice President of corporate development for Life Technologies (NASDAQ: LIFE) and a Vice President in the equity research group at Deutsche Bank covering Life Science Tools. Dr. Walker has a BA in Biology from Swarthmore College and a Ph.D. in Human and Molecular Genetics from Baylor College.


Professor Yun Yen, M.D., Ph.D.

City of Hope, Molecular Pharmacology
Dr. Yen is a Full Professor and Chair of the Department of Molecular Pharmacology and Staff Physician of Medical Oncology, and Director of the Molecular Pharmacology Department at the Beckman Research Institute of the City of Hope in Duarte, California. He leads the translational research at City of Hope. The translation work focuses on early marker detection, genome medicine, and targeted therapy. He serves several positions at City of Hope which include Associate Director for Translational Research, Comprehensive Cancer Center; Dr. & Mrs. Allen Y. Chao Chair in Developmental Cancer Therapeutics, Endowed Chair; Co-leader, Developmental Cancer Therapeutics Program, Comprehensive Cancer Center; Professor and Chair, Molecular Pharmacology; and Interim Chair, Medical Oncology & Therapeutics Research. Dr Yen obtained his Ph.D. from Thomas Jefferson University, Philadelphia, PA, Pathology & Cell Biology, and his M.D. from Taipei Medical College, Taipei, Taiwan.


Stephen Young, Ph.D., D(ABMM)

TriCore Reference Laboratories and University of New Mexico
Stephen Young, Ph.D., received his B.S. and M.S. in Biological Sciences from Wright State University and his Ph.D. from the University of New Mexico. He completed an American Board of Medical Microbiology (ABMM) post-doctoral fellowship program at the University of Washington. Dr. Young has been a Diplomat of the American Board of Medical Microbiology for last 21 years. Dr. Young rose through the academic ranks at the University of New Mexico achieving the rank of Professor in the Department of Pathology. His primary responsibility in his academic appointment at UNM was to be the Director of Clinical Virology and with the formation of TriCore Reference Laboratories, in 1998, he assumed the responsibilities for both Microbiology and Virology. Dr. Young served as the Director of the Infectious Disease Section for 17 years. Along with his service responsibilities was funded for ten years by Sandia National Laboratories working on the development of long range sensors for biodefense. Dr. Young has been a collaborator for 25 years in the Multi-Center AIDS Cohort Study is active on several NIH grants affiliated with this cohort. Dr. Young’s has active research in evaluation and development of diagnostic products for clinical microbiology and has completed approximately 100 FDA in vitro diagnostic device trials or market evaluations of diagnostic tests. Recently, Dr. Young retired from the University of New Mexico, but remains as faculty as Professor Emeritus in the Department of Pathology to continue a research contract. Dr. Young is now in a new role as Director of Research and Clinical Trials at TriCore Reference Laboratories.


Directors

George J. Lee, Ph.D., Chairman

Co-founder and Managing Director of Amkey Ventures and Eureka BioVenture Partners. Co- Founder of Pharmout Labs, Pharmdel Inc., BioKey Inc. Former Chairman of Epitomics, Inc. (acquired by Abcam Ltd.). Board member of several companies, include Renal Solution (acquired by Fresenius Medical Care), Panomics, Inc. (acquired by Affymetrics), StemCyte, etc. Ph.D. in Chemistry, State University of New York at Buffalo.


Richard Chang

Richard Chang is the President & Managing Partner of iD TechVentures. iDT VC is an active early stage tech venture investor managing total fund size of US$300M. With more than 24 years' experience in finance and operations management, Mr. Chang involves in investment strategy and direction, has recorded 10 more successful IPO companies. Mr. Chang has worked in Acer Group for 25 years being Manager of Corp. Auditing, AVP & Controller of International Sales Division, CFO of Acer Computer International Ltd. (ACI) and GM of ACI, Taiwan. He played a key role for ACI's long term growth.


Winston Z. Ho, Ph.D.

Founder and CEO Maxwell Sensors, Inc., Director of Sensor Systems at Intelligent Optical Systems, Inc., Director of Biomedical Optics at Physical Optics Corp. 52 published papers and 15 issued patents. Winston Ho served as an SPIE program committee and NIH grant review committee. MS Biochemistry and Ph.D. Biophysics from Arizona State University, and then worked as a postdoctoral fellow at Columbia University in New York and a Research Scientist at University of Arizona (Optical Science Center).


Benjamin Jen, M.S.

Founder and Managing Partner of GRC /GVT Capital Fund. Mr. Jen has more than 20 years of management and operational experience in venture capital and technology industry. Former Head of Corporate Investment of Quanta Group. MS from Massachusetts Institute of Technology Sloan School, BS degree in Computer Engineering from University of Missouri Columbia.


Edward Yang

Partner of iD Ventures America. Retired VP/CTO of Personal Systems Group and Computing Systems Organization at HP, Co-Leader for Enterprise Systems of HP/Compaq merger, General Manager, Singapore Networks. BS degree in EE from National Cheng-Kung University, Engineering Diploma from Philips International Institute, MS in EE from Oregon State University.